Ric Kayne Files Definitive Proxy Materials for Athira's 2022 Annual Meeting
Sends Letter to Athira’s Shareholders Seeking Replacement of CEO Dr. Mark LittonHighlights New Management and Shareholder Centric Directors Are Required to Provide Proper Oversight of ATH-1017 Clinical Trials to Maximize Likelihood of SuccessUrges ATHA Shareholders to VOTE the BLUE Proxy Card NEW YORK--(BUSINESS WIR...
Source: pharmiweb.com